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Colorectal cancer (CRC) is the third leading cause of death from cancer in both men and 
women in the Western world. Improved screening efforts, surveillance, and treatment have 
reduced CRC mortality in older patients. However, the incidence is increasing in young adults, 
even in the absence of CRC family history. This may indicate an influence of increasing 
obesity, changed dietary patterns, and lifestyle factors. The progression of CRC is a multistep 
procedure that takes 10-15 years, thus offering a time to implement preventative measures and 
early detection. There is a critical need to develop more effective preventive therapies due to 
the risks posed by current prevention therapies. The best CRC prophylactic agent should be 
both safe and suitable to use for a long time (1).  
In preclinical studies, estrogen has been shown to protect from CRC, and substantial evidence 
suggests it is through estrogen receptor beta (ERβ). Natural ERβ selective agonists have been 
tested in phase II clinical trials to treat menopause symptoms and proven to be safe and well-
tolerated with no side effects (2, 3). Thus, selective activation of ERβ with selective agonists, 
which do not activate estrogen receptor alpha (ERα), is a potential clinical approach in 
preventing adenomatous polyps progression into CRC. However, the mechanism of these 
beneficial ERβ effects is not well understood, and there is a significant knowledge gap in this 
area.  
The overall aim of this thesis was to identify the mechanistic background of the intestinal ERβ-
mediated antitumorigenic effects in the colon and further to explore ERβ as a preventative 
approach in CRC. One specific aim was to determine whether ERβ present specifically in colon 
epithelium is responsible for protecting from CRC, which is addressed in Paper I. To 
understand the impact of ERβ in protecting from colitis-associated CRC (CA-CRC), we have 
induced colitis in intestinal-specific ERβ knockout mice of both sexes. The loss of intestinal 
ERβ aggravated CA-CRC in a sex-dependent manner. The incidence of tumors increased in 
males, while in females, the size of the tumors was enhanced. We identified that ERβ attenuates 
tumor necrosis factor alpha (TNFα) induced epithelial cell damage and modulates the 
regulation of key nuclear factor-κB (NFκB) members. As a direct consequence, ERβ was found 
to reduce inflammation and to control intestinal crypt cell proliferation.   
Another aim was to explore transcriptional regulation by ERβ through mapping of chromatin 
binding sites and interaction with NFκB, which is studied in Paper II and IV. Commonly used 
ERβ antibodies have been shown to be unspecific towards ERβ; this study used a validated 
ERβ antibody to map genome-wide ERβ binding sites in colon cancer cells. We observed that 
the presence of ERβ also modulated the regulatory chromatin mark H3K27AC in potential 
enhancers of transcriptional regulation, Wnt signaling, and cell proliferation. Further, motif 
analysis indicated a novel ERβ colon-specific cross-talk with TCF, and KLF motifs supported 
a interaction between β-catenin/TCF and ERβ. We found that ERβ binds and regulates several 
important tumor suppressors and oncogenes in CRC cells, such as CST5 and LRP6, consistent 
with its proposed antitumorigenic activity. We also revealed the p65 cistrome in CRC cell lines 
and showed that ERβ alters the p65 chromatin binding in a cell-type-dependent manner. We 
found that ERβ chromatin binding sites were enriched among circadian clock genes and also 
that ERβ modulates p65 binding to core clock genes in CRC cells, indicating potential cross-
talk between ERβ and circadian clock gene regulation.    
The final aim was to investigate the impact of ERβ, and estrogen signaling in high-fat diet 
(HFD) induced inflammation in colon, explored in paper III. We fed mice with an HFD for 13 
weeks and treated them with estrogenic ligands for the last three weeks prior to sacrifice. The 
colon transcriptome showed predominant sex differences, and selective activation of ERβ 
reduced macrophage infiltration and epithelial cell proliferation induced by HFD. We 
demonstrated that ERβ opposes HFD-induced dysregulation of core circadian clock genes in 
vivo, further strengthening the role of ERβ in circadian rhythm. 
Taken together, these results highlight the chemopreventive potential of ERβ in CRC in both 
sexes. The identified cross-talk with TNFα/NFκB pathway, Wnt signaling, regulating genes 
involved circadian clock, and tumorigenesis reflected ERβ protection/antitumor activity 
against CRC progression and development (as illustrated in Figure 1).   
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Globally, we have entered an era of increased living standards and affordable access to quality 
healthcare with better diagnosis methods and treatment of diseases. Life expectancy is also 
raised in most parts of the world as a result of access to health care. Improved medical 
treatments, however, have decreased death rates primarily from communicable diseases. By 
contrast, cancer-related deaths have increased by 40% over the past 40 years. A further 60% 
increase in cancer deaths was expected by 2030, with an estimated 13 million people dying of 
cancer, as reviewed in (4, 5). However, a recent study in the US population reported a 26% 
decline in the cancer death rates over two decades (6). Colorectal cancer (CRC) has become a 
leading cause of cancer, affecting 1.23 million patients each year and accounting for 10% of 
cancer-related deaths in Western countries (4, 5). 
1.1 Colorectal cancer 
CRC is defined as a tumor that originates from the colon and rectum. It is the third most 
prevalent cancer in the world, with an estimated 880 792 deaths each year, 1.8 million new 
cases, and 1.2 million deaths expected in the next ten years (7, 8). Roughly 66% of the cases 
are colon cancers, and the remaining are rectal cancers (9). After lung, breast, and prostate 
cancer, CRC is the fourth most common malignant tumor in terms of incidence, yet it is ranked 
the third in regards to cancer mortality (8).  
1.1.1 Epidemiology 
Colorectal cancer classifies as a symbol of socioeconomic growth, and, in nations experiencing 
significant development, prevalence rates are inclined to increase consistently with a high 
human development index (HDI) (10, 11). An upsurge in previously low‐risk and lower HDI 
nations signifies lifestyle changes along with diets, such as changes toward an amplified 
consumption of animal‐source diets, low physical activity, and body mass is independently 
correlated with CRC risk (12, 13).   
For decades, CRC was considered an old age disease; however, recent data indicate increased 
CRC incidence in young adults under the age of 50 (14-16). Most of these individuals under 
the age of 50 would not meet the screening criteria. One recent study identified the rise of rectal 
cancers compared to colon predominantly in young individuals (14). The rising incidence in 
young birth cohorts indicates the influence of dietary patterns, excess body weight, and lifestyle 
factors (13). 
1.1.2 Risk factors 
CRC is a complex disease being influenced by multiple factors such as aging, chronic 
inflammation, poor dietary habits, obesity, and lifestyle. The most significant risk factor for 
CRC is older age; the disease is rare before age 40 (17). Around 80% of CRC cases are 
sporadic; only 10% are caused by genetic predisposition such as Familial adenomatous 




tumor suppressor gene adenomatous polyposis coli (APC). Lynch syndrome is characterized 
by mutations in mismatch repair genes (MMR) (18, 19).  
Male gender increases the risk of CRC incidence and overall survival (17). Patients with 
inflammatory bowel disease and ulcerative colitis also have a higher risk of developing colon 
cancer (20). In CRC, substitution mutations that change single amino acids were the highest 
number of mutations indicating CRC’s are most vulnerable to environmental factors (21). 
Thus, lifestyle-related diseases, such as metabolic syndrome, cause between 40-70% in terms 
of CRC development, and diet has been shown to influence CRC risk (22-24). A recent study 
indicated that high intakes of red meat and processed meat increase the risk of CRC (25), while 
phytoestrogens or isoflavones dietary intake provided a protective effect in CRC patients (26). 
High vitamin D levels are correlated with improved survival and decreased recurrence. 
Supplementary calcium intake was associated with reduced colon cancer risk (27, 28). In the 
UK population, using a modeling approach, 5% of diagnosed colon cancer cases were 
estimated due to low levels of physical activity. A meta-analysis showed that high physical 
activity reduces the overall risk of CRC by 24% compared to the least active individuals (29, 
30).  
1.1.3 Tumor staging and subtypes 
In colorectal cancer, the tumor's pathological stage is generally considered the most critical 
determinant of outcome. The TNM classification is the most widely used, which considers 
tumor invasion, spread to lymph nodes, and metastasis to stage CRCs (31). The high degree of 
heterogeneity in CRC, at both genomic and transcriptomic levels, leads to further categories 
based on gene expression profiles.  
Consensus Molecular Subtypes (CMS) classification identified four subtypes (CMS1-CMS4) 
and helped in personalizing oncological care by distinguishing the patients who may benefit 
from adjuvant chemotherapy (32). The CMS1 subtype is associated with major histological 
changes, more often seen in women, and is linked to MMR status. The tumors of the CMS2 
are the most diverse among all, whereas the CMS3 subgroup contains a high incidence of 
KRAS mutations. The CMS4 group is considered a pro-inflammatory type due to increased 
mesenchymal and stromal genes instead of genes involved in cancer, indicating the importance 
of inflammation in CRC. The CMS4 group had the most advanced stages of CRC of all the 
groups, as well as the highest tumor budding compared to the CSM2, CSM3 subtypes(33).  
1.1.4 Diagnosis and treatments 
CRC's routine diagnosis is based on physical examinations, colonoscopy, and computer 
tomography colonography. The serum tumor marker carcinoembryonic antigen (CEA) or fecal 
occult blood is also measured using laboratory tests (FEB). In most of Europe, Canada, and 
North America, screening initiatives testing FEB and using colonoscopy are currently in 




within five years identified 0.1 percent with CRC out of 1.8 percent tested with a colonoscopy 
(35). 
Studies have been conducted using non-steroidal anti-inflammatory drugs (NSAIDs) to prevent 
CRC. NSAIDs such as aspirin and celecoxib inhibit the cyclooxygenase-2 (COX-2) enzyme, 
which induces inflammation and reduces the risk of colon cancer. Two extensive clinical 
studies revealed that long-term use of NSAIDs reduces CRC incidence by 37% (36, 37). 
However, these clinical trials stopped early due to cardiac side effects of COX-2 inhibitors such 
as celecoxib and rofecoxib (17, 38, 39). A randomized control trial of 164,225 patients 
confirmed that aspirin increased the risk of bleeding (40). Hence COX-2 inhibitors, which had 
previously been approved by the European Union (41) and the United States (42), were no 
longer used to prevent CRC, and there is a need for developing new and safe targets.  
The cure for colorectal cancer is determined by the degree to which cancer has spread. 
Complete surgical resection is the only approach in treating colorectal cancer in stages between 
I and III. Primarily, 2 out of 3 individuals who go through surgical resection will have cancer 
regrowth or metastases. Thus, to treat and prevent a recurrence, chemotherapy treatment with 
single drug 5-Fluorouracil (5-FU) or in combination with oxaliplatin, capecitabine used (43).  
1.2 Pathways involved in CRC 
Notably, the three common pathways in CRC development are chromosomal instability (CIN), 
microsatellite instability (MSI), and CpG island methylator phenotype (CIMP). Primarily, the 
CIN pathway accounts for 85% of the sporadic CRCs. It is mainly caused by chromosomal 
imbalance and loss of function mutations in tumor suppressor genes. Fundamentally, MSI is 
categorized by mutations in MMR genes regulating microsatellites in DNA replication (44). 
MSI creates frameshift mutations that inactivate genes involved in the MMR process (45). 
Aberrant methylation of CpG islands leads to epigenetic instability in CRC, and 10-20% CRCs 
contain a high percentage of methylated CpG loci (46). Nonetheless, the mechanisms leading 
to CIMP are still unknown. 
1.2.1 Molecular pathogenesis  
The evolution of colon cancer is mainly due to the progressive accumulation of genetic 
mutations through which cells acquire the ability to sustain cancer hallmarks. The six biological 
hallmarks of cancer are proliferative signaling, inhibiting growth suppressors, resisting cell 
death, evading apoptosis, and inducing angiogenesis. Genetic and epigenetic alterations 
activate oncogenes and inactivate tumor suppressor genes to enable cancer hallmarks (47). 
Aberrant colonic crypts drive the normal colonic epithelium into adenomatous polyps, benign 
tumors with malignant potency. Benign adenomas develop into carcinomas over 10-15 years 
due to the accumulation of genetic mutations primarily in adenomatous polyposis coli (APC), 
KRAS proto-oncogene, and tumor protein p53 (TP53) genes. The pathways involved in the 





Figure 2: Molecular progression of colorectal cancer. Inspired by Kuipers et al., 2015. 
1.2.2 Wnt/β-catenin signaling pathway 
Wnt signaling is a central mechanism that controls cell fate decisions which mainly acts 
through frizzled protein, low-density lipoprotein receptor-related protein 6 (LRP6) receptors. 
In a normal colon, the Wnt ligand maintains stem cell homeostasis, and the Wnt signaling target 
gene Lgr5 is a well-established marker for intestinal stem cells (48). CRC cells with high 
expression of Lgr5 clonally expand and form colonies compared to cells without Lgr5 
expression (49). High Wnt activity was observed in colon cancer stem cells and cancer 
stemness regulation (50).  
Wnt signaling is divided into two pathways, canonical, dependent on the β-catenin and, non-
canonical pathway, independent of β-catenin. β-catenin is encoded by the gene CTNNB1 and 
plays a vital role in cell morphology. Both cytoplasmic and nuclear β-catenin levels are strictly 
regulated by a group of proteins called β-catenin destruction complex, which keeps the levels 
of β-catenin low in the absence of a Wnt signal. This complex is formed by scaffolding protein 
axin, glycogen synthase kinase 3 (GSK3), casein kinase 1 (CK1), and APC protein. APC is a 
tumor suppressor gene that negatively regulates β-catenin and controls proliferation, 
differentiation, and migration promoted by Wnt signaling. APC is mutated in more than 80% 
of CRC patients (51). When Wnt binds to the frizzled receptors and LRP5/LRP6 in the 
canonical pathway, it inactivates the β-catenin destruction complex and activates β-catenin. β-
catenin, which does not possess a DNA-binding domain, interacts with TCF (T- cell factor) or 
LEF (lymphoid enhancer factor) transcription factors to regulate Wnt target genes involved in 
cell migration, proliferation, and survival such as CCND1 (cyclin D1), PTGS2 (COX-2) and 
MYC (c-Myc) (52).  
In the absence of a Wnt signal, β-catenin destruction complex phosphorylates β-catenin, while 
APC constantly ubiquitinates and degrades the β-catenin. The central region of the APC protein 
mainly coordinates with β-catenin through seven 20 amino acid repeats. APC mutations in 
colon cancer were primarily found in the third 20 amino acid repeat of the protein, which has 
been shown to be the most highly phosphorylated site with an increased affinity for β-catenin 
(53). APC gene inactivation fails to degrade β-catenin. β-catenin then increases transcription 




increasing Wnt signaling. Mutations of the APC gene have been reported as an early CRC 
mutation for the acquisition of cancer hallmark inactivated tumor suppressor genes (54). In 
FAP patient’s germline APC mutations causes hundreds of polyps in the colon and rectum (18).  
 
Figure 3. Wnt signaling pathway in colorectal cancer (Pino et al. Gastroenterology 2010, permission obtained to 
print 5055420182095) 
1.2.3 RAS/MAPK pathway 
Adenoma to carcinoma progression is initially influenced by the KRAS gene, a proto-oncogene 
encoding for an ATPase protein that transmits an extracellular signal through MAPK and 
enhances cell proliferation. Activating mutations in the KRAS gene permanently activates the 
protein to sustain proliferative signaling and avoid apoptosis. Single point mutations in codon 
12 and 13 lead to an oncogenic phenotype and are hotspot mutations in the KRAS gene (55). 
1.2.4 p53 pathway 
p53 is a tumor suppressor that regulates cell cycle arrest and apoptosis. Inactivating p53 
mutation is a common and critical molecular step in CRC progression. Loss-of-function p53 
mutations are most common (56, 57) and result in proliferative activity and resistance to cell 
death. Unlike mutations of the APC and KRAS genes, and unlike some other cancers (such as 






1.2.5 TGF-β pathway 
 TGF-β is a member of the cytokine family regulating epithelial systems and inflammatory 
processes, particularly in the gut. TGF-β receptors (TGFBR1, TGFBR2) phosphorylate 
SMAD2 and SMAD3, which then form a complex with SMAD4 and move to the nucleus to 
regulate transcriptional activity. TGF-β also maintains tissue homeostasis and regulates cell 
proliferation, adhesion, and survival. Cancer cells escape this pathway during malignant 
evolution through mutations that truncate TGF-β receptors and inactivate the SMAD4 gene 
(58, 59). 
1.2.6 TNFα/NFκB signaling 
The function of the nuclear factor of κB (NFκB) was previously thought to be immune-related, 
but oncogenic mutations activated NFκB in lymphoid cancers have revealed its important role 
in cancer. NFκB is a family of transcription factors, which regulate innate immune and 
inflammatory responses. A constitutive expression of NFκB in cancers revealed other functions 
of NFκB, such as cell proliferation, migration, and apoptosis (60, 61). There is a large amount 
of evidence suggesting NFκB participation in carcinogenesis by activating cellular gene 
expression. To date, five different NFκB family members have been identified; NFκB1 
(p50/p105), NFκB2 (p52/p100), RelA (p65), RelB, and c-Rel. NFκB protein dimers bind to the 
promoter of target genes on a standard specific sequence known as "κB site." The term NFκB 
mostly refers to p65-p50 heterodimer, which is the primary dimer in most cell types. NFκB 
transcriptional activity is dependent mainly on p65, which contains the most potent 
transcriptional active domain (61-64).  
1.3 Colorectal cancer - preventable cancer?  
As described above, the origins and causes of colorectal cancer (CRC) are many. Many risk 
factors are modifiable (17), which allows the potential prevention of most CRCs development 
(22-24).  
1.3.1 Inflammation 
Inflammation is one of the most important hallmarks of cancer, promoting cancer development 
and progression through different mechanisms (65). Inflammatory diseases such as colitis, 
pancreatitis, and hepatitis, have been associated with an increased risk of colon, pancreatic, and 
liver cancers, respectively. A prolonged inflammatory condition attracts macrophages, 
leukocytes which secrete tumor necrosis factor-alpha (TNFα), and reactive oxygen species 
(ROS). This aggravates DNA damage (66) and results in mutations (67, 68). Further, chronic 
inflammation profoundly affects metastasis through epithelial-mesenchymal transition (EMT), 
providing mobility and the ability for cells to migrate from the primary tissue (69). Through 
activation of wound healing processes, the inflammatory response augments angiogenesis and 




As an inhibitor of cyclooxygenase-2 (COX-2), a component that ranks as an important 
mediator of the inflammatory reaction, Aspirin was shown to be substantially effective in 
preventing adenomatous polyp and CRC (71, 72). However, Aspirin is not advisable because 
of the increased risk of bleeding. Frequent usage of Non-Steroidal Anti-Inflammatory Drugs 
(NSAID) is associated with a lower risk of CRC (71, 72), even though the case is different 
when there is an occurrence of BRAF mutation-caused CRC (73). However, trials with NSAID 
celecoxib have ceased due to cardiac side effects (38, 40). New treatments are necessary due 
to the risks posed by current prevention therapies.  
1.3.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) results from the chronic inflammation of the intestine 
triggered by environmental and immunoregulatory factors, unbalanced gut microbiota, and 
genetic predisposition. IBD has increased rapidly worldwide and also, 25% of the detected 
cases were below the age of 20, indicating a rise in children and adolescents (74). IBD is 
categorized into Crohn’s disease and ulcerative colitis. In many cases, Crohn’s disease has its 
effects on the entire GI tract, whereas ulcerative colitis can be termed as a disease of the large 
intestines, specifically the sigmoid and rectal parts (75). IBD is a chronic condition that can be 
clinically managed using 5-aminosalicylic acid (5-ASA), doses of immunomodulatory 
(azathioprine), and anti -TNFα drugs such as infliximab. Nonetheless, surgery may be preferred 
in certain cases (74).  
IBD increases the risk of CRC, and eventually, 20-30% of IBD patients will develop colitis-
related colorectal cancer (CA-CRC) (76, 77). CA-CRC shows a complex malignancy by 
acquiring p53 mutations at an early stage compared to the sporadic type of CRC, where APC 
mutations are the first events (78). Sex differences were identified in CRC development in 
patients with IBD; men with IBD are at 60% increased risk to develop CRC compared to 
women (20). 
1.3.3 Obesity and diet 
Epidemiological evidence suggests that having a high Body Mass Index BMI (BMI) raises the 
risk of developing CRC (79). A large cohort study conducted among ~80,000 females 
identified that being overweight was connected to an increased risk of early-onset CRC in 
women. The foremost aspects of obesity are chronic low-grade inflammation and excess 
adipose tissue, which enhances the release of free fatty acids, interrupting insulin signaling 
in the skeletal muscle (80). Also, HFD is illustrated to affect intestinal permeability, microbiota, 
along with inflammation (81-83). A new study suggests that high-fat diet advances CRC 
development upsets the balance of bile acids within the intestine, activates a hormonal signal 
that helps cancerous cells thrive. In this case, such findings could clarify why colorectal cancer, 
a disease that can take years to develop, is becoming more common in younger people, 
following current trends indicating that higher-fat diets are more prevalent. (84). Consumption 
of an HFD causes metabolic dysfunction by disrupting the systemically harmonized circadian 




during the day (86). It disrupts the rhythmicity of Clock, Bmal1, and Per2 within the liver as 
well as the adipose tissue (87) (88). In the gut, circadian rhythm plays an essential role in 
regulating intestinal permeability, cell proliferation, gut microbiota, and metabolism, and 
perturbation of this fine balance can result in IBD and CRC (as reviewed in (89)). The 
dysregulation of circadian genes results in increased pro-inflammatory cytokines plus the body 
adiposity regarding the diet-induced obese mice (86). Indeed, meta-analyses have discovered 
a relationship between night shift work, obesity, and augmented CRC risk (90, 91). 
1.3.4 Sex and hormonal factors  
There are apparent sex differences in CRC. Compared to women, the prevalence of CRC is 
significantly higher in men. More aggressive proximal CRC is most common in women, while 
men predominantly suffer from distal CRC (as reviewed in (92)). Studies have been conducted 
to showcase the varying origins and causes of both distal and proximal CRC. Men and women 
have different gastrointestinal transit times, impacting the interaction between anti-
carcinogenic, carcinogenic agents and colonic mucosa. Abnormal glucose metabolism 
promotes the growth and progression of CRC as reviewed in (93, 94), and sex differences 
highly influence glucose metabolism and DNA methylation patterns which alter insulin 
production (95). Sex hormones also play an essential role in the progression of certain cancers. 
Estrogens also impact gastrointestinal tract diseases (96, 97), including gastroesophageal reflux 
disease (98), irritable bowel syndrome, and IBD (99). 
1.4 Estrogens in CRC 
1.4.1 Estrogens  
Estrogens are steroid hormones that are regarded as necessary for sexual and reproductive 
development in women and men. Estrogens are involved in various physiological functions 
within the female body, such as bone integrity, muscle mass, subcutaneous visceral fat, 
circadian rhythm, and homeostasis (100, 101). In men, estrogens are also critical during the 
development of their reproductive organs and sex differentiation of the brain (102). 
The term estrogen denotes several chemically similar hormones within this group which 
include estrone (E1), 17β-estradiol (E2), estriol (E3), and estetrol (E4) (103). E2 is the most 
predominant circulating form of estrogen in pre-menopausal women and is 10 times more 
potent than E1 and 80 times more potent than E3 (104). The primary production of E2 is in the 
ovaries of premenopausal women. It is synthesized in the granulosa cells of the ovaries through 
a process called steroidogenesis. Dietary cholesterol, particularly low-density 
lipoprotein (LDL)-cholesterol, is the primary substrate for steroid hormone biosynthesis (103). 
Estrogens are a result of the action of aromatase, responsible for the conversion of testosterone 
to estradiol and androstenedione to estrone. The granulosa cells of the ovarian follicles and the 
corpora lutea produce E2. The synthesis of estrogens also occurs in smaller amounts in other 





In males, E2 is produced through aromatization in Sertoli cells, Leydig cells, and mature 
spermatocytes of the reproductive tract (102). In men and postmenopausal women, E1 is the 
most prominent estrogen and comes from a local synthesis of estrogens in extra gonadal target 
tissues by aromatization (105). Through this, the E1 may also be converted into E2 in 
peripheral tissues. These include adipose and breast tissue, vascular endothelium, smooth 
muscle cells, brain tissue, and bone cells (105, 107). The estrogens local production implies the 
signaling modality from endocrine to act locally as a paracrine or intracrine factor (105). E3 
and E4 are only synthesized during pregnancy by the placenta and fetal liver, respectively (108, 
109). All estrogens can bind to nuclear and membrane estrogen receptors, but their affinity and 
strength of the response vary. The most potent among all estrogens in inducing cell 
proliferation is E2, followed by E1 and E3 (110).   
A recent study conducted using gastric biopsies found that parietal cells produce large amounts 
of estrogens within gastric mucosa and eventually secrete them to the portal vein (111). It is 
hypothesized that gastric E2 binds to the ER and controls certain functions or is metabolized 
into inactive estrogens by liver (112). Thus, it explains the pathophysiological importance of 
estrogens in gastrointestinal tract.  
1.4.2 Estrogen receptors alpha and beta 
Estrogen receptors (ERs) are the mediators of estrogens (102, 103). Estrogen mainly acts 
through three receptors, estrogen receptor alpha (NR3A1/ESR1), estrogen receptor beta 
(NR3A2/ESR2), and G protein-coupled estrogen receptor (GPER1, see below). ERα and ERβ 
are nuclear receptors. Nuclear receptors (NRs) are multifunctional proteins transducing signals 
of their cognate ligands. Humans have 48 nuclear receptors, including steroid, thyroid, vitamin 
D, and retinoid receptors. These are involved in signal transduction and act as ligand-inducing 
transcriptional regulators which control the activity of specific gene networks. They can be 
divided into three categories: endocrine NRs, orphan NRs and adopted NRs based on ligand 
binding. Endocrine NRs rely on hormones as their endogenous ligands, such as ERs. Orphan 
NRs have no known natural ligand, while adopted NRs have their natural ligand discovered 
after previously being considered orphans (113). The various forms of NRs include monomers 
(steroidogenic factor-1 (SF-1), estrogen-related receptor β) (114) and homodimers (ERs, and 
androgen receptors (AR), heterodimers with other nuclear receptors (retinoid X receptor 
(RXR), thyroid receptor, and vitamin D receptor (VDR), among others (115).  
The most researched NR functions are the ones of AR in the prostate and ER in the breast. 
AR is a steroid receptor for testosterone which is a critical driver in prostate cancer, and 
several anti-androgen drugs are in use to reduce AR activity (116). ERα initiated and 
proliferate breast cancer, and a majority of the breast cancers contain ERα expression and 
responds to hormone treatment (117). About 70% of NR binding sites were prominent in 
open chromatin (113, 118). Nevertheless, NRs recruit a variety of chromatin-modifying 




HNF4, ER, LRH1, PPAR, VDR, RXR, RAR and LXR are the nuclear receptors expressed in 
the colon (113, 119). In both mouse and human models of CRC, the enteric NR transcriptome 
is downregulated during tissues' progression from normal intestinal epithelia to dysplastic 
lesions. Therefore, a therapeutic, diagnostic potential is proposed for these transcription factors 
in CRC (120, 121). 
ERα was discovered in 1968 (122), and after 27 years, the second distinct estrogen receptor 
ERβ was identified in rat prostrate by the Gustafsson group. The ERα and ERβ genes are 
located on different chromosomes (6q25.1 and 14q22-24) (123-125). ERα is mainly expressed 
in the endometrium, ovary, mammary gland, bone, uterus, smooth muscles, and epididymis 
within the human body. On the other hand, ERβ can be found in the ovaries, testis, adrenal 
gland, and spleen (126).  
1.4.3 ER structure 
All nuclear receptor proteins are composed of a variable N-terminal domain (NTD), a DNA 
binding domain (DBD), a hinge region, a conserved ligand-binding domain (LBD), and a 
variable C-terminal domain. The DNA binding domain has two zinc finger motifs that serve 
as hooks and facilitate binding to chromatin in the nucleus. Each class has its own DNA 
binding recognition sequences, which is a distinguishing feature. Nuclear receptor ligand-
binding domains are functionally quite similar, but their specificity and affinity for particular 
ligands differ (127).  
Estrogen receptors are composed of five functional domains. Beginning from NH2- to COO-
terminus, Activation function 1 (AF1) and NH2 terminal domain (NTD) forms domain A/B, 
DNA binding domain (DBD) forms domain C, domain D is hinge region, ligand binding 
domain (LBD), and Activation function 2 (AF2) located within domain E and domain F in C-
terminal of protein.  
The NTD/AF1 domain is capable of ligand independent activity through phosphorylation and 
subsequent transcriptional activation of target genes (128, 129). DBD recognizes specific DNA 
sequences denoted as estrogen response elements (ERE) in target genes, facilitating ER binding 
to stimulate or repress the transcription of these genes (130). LBD/AF2 domain contains a 
hormone-binding pocket that facilitates ligand binding and dimerization. The orientation of the 
AF2 domain determines the functions activated by ligands as an agonist or antagonist (131). 
Besides, AF1 and AF2 are important regions that activate transcription and interact with other 
nuclear receptors or co-activators (132). The DBD and LBD are connected by the D domain, 
which includes amino acids that are important for post-translational modification (133). 
Additionally, the F domain controls the transcription of genes in a cell specific and ligand 
independent way (134, 135).  
DNA-binding domains of ERα and ERβ are highly conserved, but the two nuclear receptors 
differ significantly in their N-terminal domains and in their ligand-binding domains. At hinge 




strongly bind estrogen, the overall homology of their ligand-binding domains is less than 55%, 
which has enables the development of receptor-selective ligands (124, 134, 136).  
1.4.4 ERβ splice variants 
ESR2 contains eight encoding exons, which spans 254 kb, and it has several isoforms due to 
alternative splicing of the last coding exon (137). These isoforms are modified in the 3’ end 
of hERβ1(wild type ERβ) (Figure 4). Of all, wild-type ERβ (530 aa) is the only isoform that 
binds to the ligand (7). ERβcx can heterodimerize with ERα, hence widely seen as a 
dominant-negative receptor for ERα (138, 139). It has since been established in a recent study 
that ERβ splice variants ERβcx and ERβ5 are present in granulosa cell tumors (140). The 
study, however, does not clearly outline their roles in the pathogenesis and progression of 
cancer (137, 140). 
There is evolutionary conservation of ERs between species (141). Rodents have two known 
ERβ splice variants: a full-length rat and mouse ERβ WT isoforms (549 amino acids), with 
a sequence similarity of 99% (131) and both mouse and rat ERβ2 isoforms with an 18-amino 
acid insertion in the LBD that leads to decreased ligand binding affinity of estrogen (142-
144).  
 
Figure 4. Estrogen receptor beta contains five domains, and all splice variants of ERβ identified in humans vary 
in F domain and the structural similarities between ERα and ERβ.  
1.4.5 GPER1 
The third estrogen receptor is GPER1 (G protein-coupled receptor 1) (145). This receptor does 
not share structural similarities with ERα or ERβ and is not a transcription factor (146, 147). 
The G-protein coupled receptors (GPCRs) family entails the biggest cell surface receptor and 
contains seven transmembrane domains (148). Compared to other estrogen receptors, GPER1 
has a poor binding affinity to ligand E2 (17β-estradiol) and requires high levels of ligand to 
become activated (149, 150). However, once activated by E2, GPER1 produces rapid responses 
and activates intracellular signaling cascades by increasing cAMP production (151) and 




various physiological functions in human tissues and organs, such as nervous, immune, 
reproductive, cardiovascular mechanisms, and cancer development and metastasis (152). The 
rest of this thesis will not focus on GPER1, and ER will refer to ERα and ERβ. 
1.4.6 Ligands 
Estrogen is an endogenous ligand that activates ERs. Nevertheless, numerous other compounds 
presenting estrogenic effects that structurally or functionally resembles mammalian estrogens 
are recognized. Such compounds include phytoestrogens (naturally synthesized by plants) 
(153) and xenoestrogens (synthetic chemical compounds) from medicinal drugs, food 
additives, and plastics or environmental contaminants (154-156). Phytoestrogens can activate 
both ER’s. Some phytoestrogens such as genistein, coumestrol, and liquiritigenin are more 
selective to ERβ based on their capability to bind to LBD with a higher affinity in comparison 
to that of ERα (157-159).  
Whether natural or synthetic, ligands may be categorized as selective estrogen receptor 
modulators (SERMs), agonists, or antagonists. Agonistic ligands bind to ERs and trigger them, 
whereas antagonists block ERs activity upon binding. Agonists and antagonists bind at the 
exact position of the ERs LBD with different binding alignments. Agonist rearranges the 
ligand-binding domain conformation, creating helix 12 to rotate in a way to enable the free 
recruitment of co-activators while at the same time removing the co-repressors. By contrast, 
the antagonist disturbs helix 12 conformations to hinder association with co-activators (160, 
161). 
SERMs are a collection of synthetic nonsteroidal compounds that act as both agonists and 
antagonists of ERs, depending on the tissue type or estrogen receptor type. SERMs display 
antagonism in breast and uterus and a more agonistic nature in bones and liver (162). For this 
reason, they are utilized for the management of ERα-positive breast cancer (antagonism) and 
the deterrence of osteoporosis after menopause (agonism). A classic example is tamoxifen 
which acts as an antagonist in breast but as an agonist in uterus (163). Consequently, even 
though tamoxifen is the favored drug for treating ER-positive breast cancer, it can also prompt 
endometrial cell development and increase endometrial cancer risk (164, 165). 
Another group of SERMs binds to only one of the ER subtypes. The ERα-selective agonist 
4,4',4"-(4-propyl-1H-pyrazole-1,3,5-triyl) trisphenol (PPT) and the ERβ-selective agonist 
diarylpropionitrile (DPN) were used in the studies presented in this thesis. Notably, PPT binds 
to ERα with a 410-fold selectivity over ERβ (166), whereas DPN binds to ERβ with 70-fold 
selectivity over ERα (167). 
To circumvent the classic actions of estrogens, such as stimulation of uterine proliferation, 
pathway-selective estrogen receptor (ER) ligands such as WAY-169916 were developed (168). 
WAY-169916 has shown strong anti-inflammatory activity in synoviocytes obtained from 




17β-diol (3βD) have been shown to interact with the ERs (170, 171). One recent study also 
identified ketamine and its metabolites as a regulator of ERα (172). 
1.4.7 ER Signaling pathways 
ERs trigger transcriptional procedures and signaling events through direct binding to estrogen 
response element (ERE) in gene promoters or enhancers (genomic effects) or through processes 
that do not comprise a direct binding to the DNA (non-genomic effects),  Figure 5 (103). 
Direct genomic signaling: ERE-dependent nuclear signaling  
In the classical pathway, ligand-activated ERs translocate into the nucleus, dimerizes, and binds 
directly to the consensus ERE sequence or estrogen half-sites. ERE is a 13-bp palindrome with 
a 3-bp spacer (5’-GGTCAnnnTGACC-3’), and ERE half-sites are either the proximal or distal 
half of the palindrome (173, 174). However, certain estrogen‐responsive genes comprise EREs 
that diverge from the consensus through one or more nucleotides as well as being less potent 
regulators of the transcription than the consensus ERE (175). Nevertheless, regarding half ERE 
sites 5′‐TGGGCTCA‐3′, controversy arises about whether ER can bind to these sites (176). A 
study that incorporated genetic deletions within the ER-bound enhancers by utilizing CRISPR 
in MCF7 cells showed that two enhancers containing half EREs could not compensate for the 
full ERE site and indicate that the position of full ERE immensely affects the enhancer activity 
(177).  
It can be noted that homodimers (ERα-ERα or ERβ-ERβ) and heterodimers (ERα-ERβ) can be 
formed by ERs based on the tissue type and ligand. Even though ERα and ERβ selectively bind 
to EREs with similar affinity in vitro, the mechanism and degree of transcription that the ERs 
control significantly differs via the ERE‐dependent signaling pathway (173, 178). In vitro gel 
shift assays have shown that compared to ERα, ERβ has lower binding to non-consensus EREs, 
which account for most estrogen-responsive elements (e.g., FOS, JUN, pS2, CTSD) (179). 
Indirect genomic signaling: ERE-independent nuclear signaling 
Unlike the classical pathway, countless ER binding sites lack ERE components (180-182); 
nonetheless, ER’s control the transcription of these genes through an approach called 
transcription factor cross-talk (183-186). As stated by the most current studies, a projected 35% 
of genes that are targeted by estrogen do not contain EREs (103). Previous studies (187-190) 
have revealed the potential of ER to coact or tether with a range of coactivators, for instance, 
activating protein-1 (AP-1), stimulating protein 1 (Sp1), RUNX1, and NFκB. A cross-talk 
between ERα and NFκB has been studied. A few studies (191, 192) report that ERα represses 
NFκB activity, but on the contrary, other studies report that ERα enhances NFκB activity (193, 
194) using the same cell lines.  
The most widely studied ER coactivator is AP-1. ER bind members of AP-1 complex (Jun/Fos 
heterodimer) transcription factors. Indeed, mapping ER binding sites across the genome shows 




showed opposite transactivation of the AP-1 site: E2 activated transcription via ERα, while 
inhibited via ERβ (196). This was also noted in cyclin D1 gene expression, where E2-bound 
ERβ reduced expression of cyclin D1 and further blocked ERα-mediated activation of cyclin 
D1, as reviewed in (103). 
Additionally, several estrogen-responsive genes lacking full EREs have ERE half-sites or 
binding elements for the orphan nuclear hormone receptor SF-1 [SF-1 response elements 
(SFREs)], serving as direct ER binding mechanisms (197). Several studies indicate that ERα, 
but not ERβ, binds to SFREs (198) and transcriptionally stimulates the SP1 component (199). 
Notably, studies point out many dissimilarities in ERβ and ERα coordinating with cofactors.  
Figure 5. Different modes of ER signaling, including genomic, nongenomic, and signaling through growth 
factors. Inspired by Morselli et al., 2018. 
Indirect signaling: membrane receptors, mitochondrial events, signaling molecules 
The ERs exert cell-specific immediate effects by activating signaling molecules such as the 
Ras/MAPK pathway and cAMP. Activated kinases phosphorylate the ERs in the N-terminal 
domain, causing receptor dimerization, binding to DNA, and initiation of gene expression in 
a ligand independent fashion (131, 200). Furthermore, estrogen that binds to GPER1 also 
stimulates estrogen-dependent stimulation of adenylyl cyclase and epidermal growth factor 
receptor (EGFR). Also, methylation, acetylation, ubiquitination, and sumoylation can 




The rapid effects of estrogen, such as increased cAMP concentration in minutes (without 
gene activation), suggest that ERs confined within the plasma membrane are accountable for 
this action (202, 203). Some studies indicated that post-translational modifications such as 
palmitoylation increase the receptor’s association with the plasma membrane. In the plasma 
membrane, E2 drives cell survival through ERα non‐genomic signaling and cell death 
through ERβ non‐genomic signaling (204). Additional to the plasma membrane, ERs have 
been reported in organelles such as mitochondria (205) and the endoplasmic reticulum (149, 
206). However, ERs non-genomic activity is not as well understood as the genomic pathways, 
and additional research is required in this area.  
1.4.8 Enhancers and epigenetic mechanisms   
ERs primarily control gene expression by binding directly to sequence-specific elements in 
DNA. Only 3% of ER binding sites are in proximal promoter area (within 5 kb) of the targeted 
gene, while the rest are present at distal regulatory components. These are named enhancers 
(181, 182) and can regulate transcription processes over extensive distances of countless 
thousand base pairs and from a location downstream or upstream of the location of 
transcription initiation (207). Enhancer activity models have elucidated the looping of 
chromatin. An enhancer far away in the distance from its target promoter on a linear 
chromosome can be brought into proximity in 3D space (208). 
Some studies established ER functions via chromatin looping that brings transcriptional 
regulatory complexes of enhancers with the specific target promoters, connecting the ERs 
activity at distal locations to transcriptional start sites (TSSs) (209, 210). Chromosome 
conformation capture (HiC) detects chromatin interactions and, with the use of deep 
sequencing, maps these interactions in the 3D organization of the genome. This recent 
advancement has revealed that most of the enhancer-promoter interactions happen within large 
organizing components (between hundreds of kilobases) of the genome designated as 
topologically associating domains (TADs) (211). The utilization of the same technique shows 
that E2-ERα prompts global chromatin restructuring in MCF7 cells (212) and reorganizes open 
and highly transcribed chromatins, permitting genes to share the transcriptional complex and 
regulatory elements as reviewed in (201). 
Genome-wide studies also suggested that many enhancers and promoters contain a typical 
histone mark. Histones flanking active promoters are marked by H3K4me3, while enhancers 
are marked by H3K4me1, with both marked by H3K27ac after activation (213, 214). 
Moreover, within the locality of highly expressed genes, multiple transcription factors are 
recruited to initiate transcriptionally more active clusters of enhancers in relatively small 
sections of DNA. These are called super-enhancers which regulate cell type-specific and 
disease-related genes, including oncogenes (215, 216). Super-enhancers can be categorized as 
coregulated loci, by computationally detecting peaks containing high transcription factor 
binding levels and intersecting with dynamic chromatin marks, such as H3K27ac and DNase I 




Enhancer RNAs are also hallmarks of active enhancers and are involved in enhancer activation 
and functional activity (218, 219). These are non-coding RNAs that are transcribed at 
enhancers as a result of RNA polymerase II action. A fascinating likelihood is that enhancer 
RNAs might partake in a structural task in developing or preserving enhancer-promoter loops. 
Indeed, new data supports this theory (220, 221).   
1.5 ERβ role in CRC 
1.5.1 Major challenges in the field 
It has been 25 years since ERβ was discovered; however, ERβ expression and distribution in 
tissues and cells is unclear and still debatable. ERβ expression and its role in MCF7 (breast) 
and LNCaP (prostate) cancer have been extensively studied, in contradiction with clinical 
parameters. Further, ERβ is not present at the mRNA level in most cell lines. Fifteen out of 934 
cell lines show ERβ expression based on RNA-Seq data (222). Only B-cell lymphoma and 
ovarian granulosa cell lines expressed ERβ. Although ERβ antibodies detecting protein 
expression, irrespective of mRNA raises the question of antibody specificity. Nonspecific 
antibodies are indeed a major problem in research (223, 224). 
Our group made efforts to study and validate extensively used ERβ antibodies. We reported 
that the most widely used ERβ antibodies (14C8, PPG5/10) are not specific to ERβ protein. 
We have identified that only one of 13 antibodies (PPZ0506) specifically targets ERβ, and this 
antibody was not widely used. Using this validated antibody (PPZ0506), we have detected ERβ 
expression in human testis, ovary, granulosa cell tumors, and colon (225, 226). During the same 
period, Nelson and colleagues also reported the use of unspecific ERβ antibodies in research 
(227). A comparative study between WB and IHC has shown that antibody performance 
depends on the application and suggested validating antibody for the intended application.  
The use of unspecific antibodies in literature raises the question of functional significance of 
ERβ, and caution must be exercised in interpreting data obtained from such experiments. 
Therefore, unspecific antibody-based data was excluded from the literature review, and only 
results also supported by mRNA evidence were considered.  
1.5.2 Epidemiological evidence 
It is a well-established fact that sex plays a vital role in CRC progression and survival. Men 
have increased progression and decreased survival compared to women of all ages (228, 229). 
Men with inflammatory bowel disease are at a 60% higher risk of developing colon cancer than 
women (20). Women benefit from significantly longer survival after rectal cancer resection 
than men. These results indicate that sex steroids may protect women from colorectal cancers 
(230, 231). Though not initially designed to explore CRC risk, the Women Health Initiative 
study established that use of hormone replacement therapy (HRT) protects women from CRC 
by reducing the risk up to 30% (232, 233). HRT is a combination of estrogen and progestin, 
and several studies have shown that estrogen alone contributes to large protective effects (234, 




approximately 14% (236). Consequently, oophorectomy (the removal of ovaries) in women 
increased CRC risk by 30% (237). These findings suggest that estrogen may protect against 
colon cancer, but the mechanisms by which this occurs remain unclear.  
A meta-analysis study showed that soy consumption, which is rich in phytoestrogens, is 
associated with a 21% reduction of CRC risk in females but not in men, concluding that soy 
supplementation is synergistic with estrogen in vivo (238). Additionally, when individuals 
travel from an Asian nation to the United States, the occurrence of CRC in the immigrants 
increases to the average levels seen in the United States, indicating lifestyle and 
environmental factors role in etiology (239). Amongst the aspects related to the so-
called western way of life, obesity occupies an important risk element regarding CRC. 
Notably, a positive relationship between the BMI and the frequency of colonic adenoma and 
advanced polyps was revealed in moderately young persons of both sexes and in 
premenopausal women with estrogen effects (240). 
1.5.3 CRC suppression by ERβ 
While ERα is upregulated in several cancers, most notably in breast cancer, where it promotes 
cell proliferation, ERβ expression appears to decrease during cancer progression. At the mRNA 
level, ERβ is lost in CRC while expressed in non-tumor colon tissue. ERβ has been identified 
as the predominant ER type in colon in many studies, while ERα protein is not detected in the 
colonic epithelium or CRC (241).  
In ERα-knockout mice using the AOM tumorigenesis model, soy protein was shown to protect 
ERα-knockout mice and WT mice from colon cancer (242). However, studies in 
ovariectomized ApcMin/+ mice treated with coumestrol and genistein showed that coumestrol 
lowered tumor number in the colon and small intestine while genistein was found to have no 
significant effect (243). However, estrogen has been shown to mediate protective effects in 
wild-type mice, but not in ERβ-knockout mice, supporting ERβ as a mediator of these effects 
(244).  Therefore, the protective effects of CRC from E2 could depend on colonic ERβ (245).  
Saleiro et al. demonstrated that in females, whole-body deletion of ERβ causes an increase in 
colon adenomas and size in the AOM-DSS mouse model. Besides, they found that the loss of 
ERβ increased the levels of β-catenin and inflammation related molecules (246). However, 
using the same model, a study by Heiman et al. found that ovariectomy protected female mice 
from colitis-associated tumor development and estradiol and medroxyprogesterone acetate 
(MPA) or both promoted tumorigenesis. Using ER mutant mice, they concluded that estrogen 
depends on ERα and ERβ for protumorigenic effects (247). 
A recent study using different colitis models induced by 2,4,6-trinitrobenzenesulfonic acid 
(TNBS) showed that E2 reduced the expression of pro-inflammatory cytokines. Interestingly, 
the authors also noted increased proliferation and reduced apoptosis in ERβKO mice and 
suggested the differential protective effects of E2 in presence and absence of ERβ (248). 




both colitis models (DSS and TNBS), indicating the importance of ERβ in the protection 
against colorectal tumors (246, 248). Similarly, enhanced intestinal tumorigenesis was 
demonstrated in ERβ knockout ovariectomized ApcMin/+ mice (249).   
Along with those above epidemiological and animal studies about estrogen and ERβ protective 
effects, there is significant evidence supporting tumor suppressive activity of ERβ in cell line 
models. Re-introduction of ERβ in human colon cancer cell lines (SW480, HT29 and HCT116) 
downregulates IL6 inflammatory marker and reduces the expression of numerous oncogenes, 
for example, MYC, MYB and PROX1 (250, 251). Strikingly, ERβ has been shown to increase 
p53 signaling and reduce β-catenin levels, which increased apoptosis and reduced cell 
proliferation in LoVo colon cancer cells (252). These studies combined strongly support a role 
for intestinal ERβ as a target for chemo-preventive therapy in colon cancers, however, the 
molecular mechanisms behind ERβ function are not well understood. 
1.5.4 ER cross-talk 
To coordinately regulate target genes, ER’s recruit several transcription factors as partners to 
activate or repress hundreds of target genes at once (181, 190, 253). Many studies have shown 
a potential cross-talk between ERα and other transcription factors; only a few studies were 
conducted on ERβ cross-talk. Although ERβ shares several transcriptional mechanisms with 
ERα, there are unique ERβ mechanisms. ERβ undergoes conformational changes specific to 
each ERE, which result in the recruitment of differential coactivators (254). While both ERs 
have almost identical DBDs, ERβ has a lower affinity to ERE half-sites than ERα (255, 256). 
These differences between half-site binding and ERE-dependent conformational changes could 
contribute to the differences between ERα and ERβ in transcription activity (257). 
Previous studies have identified many pioneering factors and coregulators crucial for 
transmitting the hormonal signal to the transcriptional machinery. FOXA1 is identified as a 
pioneer factor that binds to condensed chromatin allowing the recruitment of other transcription 
factors to the DNA (258). Particularly, FOXA1 reprograms ERα recruitment at cis-regulatory 
components in breast cancer cells (182). Numerous sequencing initiatives, along with further 
research, identified regulators of ERα (FOXO3A, FOXM1, GATA3, ERBF-1) (259), as well 
as ERβ (CREB in endometrial cells (260), AP2α in prostate cancer cells (261), and 
Clock/Bmal1 in mouse models (262). Recently a couple of studies reported that tet 
methylcytosine dioxygenase 2 gets involved in ER complex along with GATA3 and acts as a 
necessary component for ER binding to chromatin (263, 264).  
Several studies reported that different steroid receptors and transcription factors modulated p65 
chromatin binding. In the breast cancer field, numerous studies indicated that ERα represses 
p65 to exert anti-inflammatory activity (265-268), whereas some studies have shown that ERα 
and p65 work together to increase gene transcription synergistically (189, 269-274). It is, 
therefore, unclear whether ERα and p65 activate or repress each other, but an interaction 
between ERα and p65 has been consistently reported. In a study, Franco et al. (275) revealed 




in increased production of enhancer RNA transcripts, an activity linked beforehand to enhancer 
activation by ER (276). 
The interaction between ERα and NFκB is shown at the baculoviral inhibitor of apoptosis 
856repeat-containing 3 (BIRC3) target gene. TNFα activated NFκB binds to the BIRC3 
promoter and prepares it for ERα binding, which in return enhances TNFα-induced BIRC3 
activation (277). Besides, TNFα intensely transforms the ERα enhancer setting in an NFκB-
dependent fashion (275, 278). Our group has reported that also ERβ regulates NFκB target 
genes, including downregulation of Il-6, which is the main target of the NFκB pathway (279). 
However, there is no data available for ERβ coactivators in colon cells, thus understanding the 
cross-talk between ERβ and its co-activators is essential for understanding its function. Based 
on that, in this thesis, I am exploring whether ERβ and NFκB interact specifically in colon 
cancer. Learning more about NFκB signaling and how it is influenced by estrogen signaling 
should lead to better therapeutic approaches in the future to target it in specific cancer types. 
1.5.5 ER cistrome studies 
Albeit ERα inhibitors have been utilized in clinics since the 1980s, the mechanism of ERα’s 
genomic activity on a genome-wide scale remained mysterious for a long time (280). Primary 
progress of chromatin immunoprecipitation (ChIP) together with DNA microarray analysis 
(ChIP-on-chip) techniques, ERα genomic binding, was identified on a genome-wide scale for 
the first time (182). Through the expansion of high-throughput sequencing methods, several 
ERα ChIP-Seq studies were executed in cell lines and some in tissues (281). Almost 95% of 
the entire ERα-binding locations are premised at distal cis-regulatory components (henceforth 
labeled as ‘cistromics’) that later acquired recognition as enhancer areas (280, 282). 
Several studies have been published on ERβ ChIP-Seq in breast mainly using exogenous 
expression of ERβ. In MCF7 cells, studies using different antibodies showed between ~400 to 
38 000 ERβ binding sites (235, 283-285). Several studies in different cell lines (286) or tissues 
(287, 288) identified ERβ binding sites somewhere between 5000 to 14 700 binding sites; few 
studies used antibodies not highly specific to ERβ. Though differing studies indicate 
changeable statistics of ER binding actions (even in the same cell line), possible because 
numerous enhancers might control a single gene (289), or certain variances are attributable to 











2 RESEARCH AIMS 
General aim  
In epidemiological and animal studies, estrogen receptor beta (ERβ) has been shown to protect 
from colorectal cancer (CRC), but the mechanisms are poorly understood. Thus, the overall 
aim of this thesis is to elucidate the role of ERβ and evaluate its potential as a therapeutic target 
in prevention of colorectal cancer. The research articles presented in this thesis identify 
molecular mechanisms of ERβ involved in preventing CRC formation and development and 
propose novel insights involved in CRC prevention. 
Specific aims  
Paper I: To test if intestinal epithelial ERβ mediates protective role in CRC, using a colitis-
induced tumor mouse model with tissue specific knockout of ERβ and to investigate any sex 
differences. 
Paper II: Determine the genome-wide binding pattern and regulation of ERβ in colon cancer 
cells and identify its cofactors.  
Paper III: Elucidate the impact of estrogen signaling in HFD induced colon inflammation in 
both sexes. 
Paper IV: Evaluate the cross-talk between ERβ and p65/TNFα inflammatory signaling in colon 










3 MATERIALS AND METHODS 
3.1 Mouse models  
Fundamentally, animal models of human disease are valuable models for studying several 
diseases, including the development of cancer. Animal models also play a crucial role in 
translating scientific studies into human disease and in predicting the future of novel therapeutic 
drug targets. The animal studies got approved by the Swedish Regional Board of Animal 
Research. In Sweden, the use of laboratory animals requires well-controlled ethical permission, 
controlled premises, and adherence to high animal welfare requirements. In the use of animals, 
the "3Rs" recommendations that encompass Replacement, Reduction, and Refinement were 
adopted in 1959 (290). Replacement: Animal experimentation is avoided wherever possible, 
and in vitro models should be used instead. Reduction: use the smallest number of animals 
required for statistical power. Refinement: reduce animal suffering and improve animal 
welfare.  
The mice were constantly provided with a regular chow diet and water and were kept on a 14-
hour light, 10-hour dark cycle. Primarily, in the paper I, CA-CRC was induced in WT mice 
and mice that specifically lack ERβ in intestinal epithelial cells (referred to as ERβKOVil). 
Regarding paper III, C57BL/6J mice with HFD-induced obesity were used.  
3.1.1 ERβKOVil mouse 
ERβKOVil mouse model maintained on C57BL/6J background strain was generated by 
Cre/loxP recombination technology. ERβflox/flox mice with ERβ exon 3 (B6.129X1- 
Esr2tm1Gust) flanked by two loxP sites were bred with transgenic mice expressing Cre 
recombinase under the control of the enterocyte-specific Villin promoter. Cre is therefore only 
expressed in the intestine, where it deletes the DNA sequence between the loxP sites in a site-
specific manner. ERβ gene exon 3 generates the first zinc finger in the DBD. Its knockout led 
to frameshift in the coding region following splicing from exon 2 to exon 4, resulting in a 
frameshift and an early stop codon, reduced mRNA levels (due to nonsense-mediated decay), 
and no ERβ protein expression. ERβflox/flox mice without Cre allele were used as controls 
(denoted as WT). The opportunity to characterize the function of ERβ specifically in the 
intestinal epithelium is a benefit of ERβKOVil mice. It is also worth noting that ERβ is lost in 
the small intestine. The full-body knockout of ERβ in mice results in phenotypes with fertility 
issues with few littermates (291), but so far, no major effects were observed in the colon of ERβ 
knockout mice in standard conditions. However, challenging ERβ knockout mice with 
inflammatory conditions or obesity mice gives more pronounced effects due to lack of ERβ.   
3.1.2 AOM/DSS-induced colitis 
Azoxymethane (AOM)/dextran sodium sulfate (DSS) model has been used extensively in 
research to mimic human CA-CRC features. The AOM/DSS induces distally located invasive 
tumors and molecular modifications in β-catenin, pro-inflammatory cytokines (TNFα), similar 




intraperitoneally injected with colonic carcinogen AOM (10mg/kg) on day 1 and then 
accompanied by colonic irritant DSS treatment in drinking water starting from day 7 to 14. The 
DSS cycle was then repeated three times, with two weeks of regular drinking water in between. 
For the duration of the DSS treatment, the mice lose weight, have diarrhea, and develop rectal 
bleeding, and all these different parameters were monitored using a score sheet. The mice 
recover during the phase of drinking normal water and, in due course, acquire colitis followed 
by adenomas. Following 9 or 15-16 weeks of AOM injection, the mice were sacrificed. 
Notably, the AOM/DSS technique has excellent reproducibility and potency, besides being a 
simple and inexpensive method of application. It is worth noting that different strains of mice 
respond differently to this treatment and that their microbiota composition can influence the 
efficacy of tumor development. 
3.1.3 High-fat diet (HFD) induced colon inflammation and obesity 
Male and female C57BL/6J mice bred in-house at the animal facility and aged 5 to 6 weeks 
were fed an HFD (60% kcal fat) or a control diet (CD) (10% kcal fat) for 13 consecutive weeks. 
The mice were treated with vehicle or estrogenic ligands, E2 (0.05 or 0.5 mg/kg), PPT (2.5 
mg/kg), and DPN (5 mg/kg) for a total of 9 injections for 3 weeks before sacrifice. The ligands 
were prepared in a mixture containing 40% PEG400, 5% DMSO, and 55% water. In 
comparison to the regular western diet, which has approximately 45% calories from fat, this 
diet has a higher fat content. The physical properties of the HFD diet, which easily breaks into 
powder, creates a problematic situation regarding monitoring the food intake. Measuring their 
exact caloric intake, and controlling their actual consumption, is therefore, a considerable 
challenge (295).  
3.1.4 Tissue collection 
Weighed colons were cleaned and opened along the axis, and the number and size of adenomas 
were recorded. The colons were fixed with 4% formaldehyde for 24 hours and kept in 70% 
ethanol before embedded in paraffin for immunohistochemistry (IHC) or the fresh tissue is 
directly frozen in liquid nitrogen for analysis, including with RNA extraction and quantitative 
reverse-transcription PCR (qPCR). Also, fresh tissues were directly embedded in OCT and 
frozen on dry ice and stored at 80°C. A pathologist who was unaware of the mouse genotype 
scored the colitis in hematoxylin and eosin (H&E) stained sections. The colitis score (0-12) 
was calculated: the severity, the extent of hyperplasia, level of ulceration, and the size of the 
affected areas were all graded between 0-3. 
3.2 In vitro studies 
3.2.1 Colon cancer cell lines  
Well-characterized cell lines enable reproducibility and resolve most of the ethical issues that 
come with using animal and human tissues. Due to these reasons, cell line models continue to 
be the most widely used in research worldwide. The foremost objective in choosing CRC cell 




for studying the genome-wide binding of ERβ. HT29 is an epithelial-like human colorectal 
adenocarcinoma cell line generated from a 44-year-old female colon adenocarcinoma tumor 
(296). The SW480 was obtained from a 50-year-old male with type B colorectal 
adenocarcinoma (297). Differences include that HT29 cells are CIMP (CpG island methylator 
phenotype) positive, whereas SW480 cells are CIMP negative. The HT29 contains WT KRAS, 
PTEN genes, and mutations in BRAF (V600E), PIK3CA (P449T), and TP53 (R273H). 
SW480, on the other hand, has WT BRAF, PIK3CA, and PTEN and mutations in KRAS 
(G12V) and of both TP53 alleles (R273H and P309S) (298). The P53 allele in the SW480 cell 
line is a double mutant, while the P53 allele in the HT29 cell line is a single mutant, which may 
result in a different chromatin complex with P65 (298). We also used ERα-positive MCF7 
breast cancer cells with tetracycline-induced expression of ERβ in paper II to compare tissue-
specific ERβ chromatin-binding between colon and breast. In Paper IV, we used MCF7 
parental cells to compare p65 cistrome between colon and breast. Due to the lack of ERβ in 
CRC cells, ERβ has been exogenously added using a lentivirus system, which has been 
generated and characterized previously (250, 251, 299). 
Cell lines were cultured in a standard cell culture medium comprising 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin. The cells were serum-starved using 1% charcoal-
stripped FBS and DMEM-phenol red-free media. Regular FBS contains hormones, such as 
estrogen and phenol (which have weak estrogenic properties). In vitro models are an excellent 
choice to dissect molecular mechanisms; however, they have a drawback when studying a 
complex disease like CRC because of the lack of tissue microenvironment that influences 
tumor growth and metastasis in vivo. 
3.2.2 Chromatin immunoprecipitation  
In many major cellular processes, such as transcription, splicing, replication, and DNA repair, 
DNA-binding proteins play crucial roles. These proteins include transcription factors that 
preferentially bind to specific sequences of DNA and histone proteins that form the nucleosome 
core, which is the chromatin's basic unit. To study genome-wide binding of transcription 
factors, chromatin immunoprecipitation (ChIP) combined with microarrays (ChIP-on-chip) or 
sequencing (ChIP-Seq) has become standard techniques (300, 301). In brief, the cells were 
cross-linked to capture protein-DNA interactions, and the chromatin was sheared into small 
fragments in the range of 200-600 bp by sonication. DNA-protein complexes were 
immunoprecipitated with an antibody specific to the protein of interest. Cross-links were 
reversed, and the released DNA was sequenced to determine the sequences bound by the 
protein (301, 302). ChIP-Seq performed with a specific antibody provides an accurate map of 
binding sites for transcription factors and other DNA-binding proteins, and this information is 
crucial for understanding biological processes. Integrating ChIP-Seq data with functional 
genomic and transcriptomic data (RNA-Seq) can provide a global view of chromatin 
accessibility and regulation of gene expression (303). ChIP-Seq is the primary technique used 




It is important to remember that each method has its limitations. From a technical perspective, 
for a high-quality ChIP experiment, a highly specific antibody and a large number of cells 
(~10 million) are usually required (304, 305). In addition to direct binding events, the 
signal from ChIP-Seq also includes indirect binding in which one factor interacts with 
another DNA-binding factor (tethering). It is essential to distinguish between direct DNA 
binding and tethering events, but this is not directly achieved from ChIP-Seq data but 
requires further analysis, in silico or experimental (301). Recent technological advances 
in the ChIP-Seq protocol have made it possible to test samples with limited cells, increase 
the accuracy of the genomic location of binding events, and test multiple binding events 
(306-309).  
The ChIP-Seq data pipeline addresses various aspects of the assessment and management of 
data: the identification of artifacts, filtering low-quality reads, estimating library complexity, 
sophisticated reading alignment and peak calling algorithms, and downstream analytical 
tooling (300). For a ChIP-Seq comparison, a common normalization approach uses the total 
number of mapped reads per million to adjust for biases generated by sequencing depth 
between samples. This approach works only to correct technical artifacts but cannot correct 
biological differences like different peak numbers. Several publications have pointed out these 
biases (310-313) and indicated the need for an initial normalization step. Various strategies 
have been employed, such as relative level difference and absolute level difference using 
synthetic histone spike in normalization (314, 315). Recently, another normalization 
strategy called parallel factor ChIP addressed these challenges by using a second antibody 
against the target chromatin as an internal control (316). Although the need for an 
exogenous spike-in is eliminated in this technique, its dependence on antibodies might 
cause reproducibility concerns. There are no gold standards available for ChIP-Seq data 
normalization and analysis. Hence the optimal method should be selected based on prior 
system knowledge and sequenced sample statistics (300, 302). There are web-based 
services such as ChIPseek (317), Nebula (318), and CSA (319) that are available to analyze 
ChIP-Seq data.  
The first method for collecting single-cell chromatin data has been published using the "Drop 
- ChIP" method (320). This method uses a droplet microfluid labeling system for individual 
cell chromatin before immunoprecipitation and reports ~800 reads per cell. Recent 
development using the microfluidic droplet method has a higher resolution with ~10,000 
reads per cell. Single-cell ChIP-Seq using this method was performed in breast cancer and 
provided a new alternative to study complex chromatin heterogeneity in tumors (321). 
3.2.3 Luciferase assays 
We performed luciferase assays to determine how ERβ, AP1, or NFκB can affect transcription 
and potentially cross-talk. The reporter gene expression is kept under the control of firefly or 
renilla luciferase. We used luciferase constructs with estrogen response element (ERE), NFκB 




promotors. Plasmid with renilla luciferase reporter was used as a control to normalize enzyme 
activity of firefly luciferase.  
Firefly and renilla luciferase are two bioluminescent forms of proteins that emit light in 
response with their substrate D-luciferin (firefly) or coelenterazine (renilla), and the produced 
light intensity is proportional to the protein concentration in the sample. The reporter gene's 
expression is directly proportional to the protein expression allowing for monitoring of small 
changes in expression.   
3.2.4 Statistical analysis 
For statistical analysis, GraphPad Prism was used (GraphPad Software Inc). The data is 
provided as a mean ± standard error of the mean (SEM). For comparison between two groups, 
a two-tailed Welch's t-test or paired t-test (if paired data) was used. For comparisons between 
multiple groups, one-way and two-way analysis of variance (ANOVA) were used, followed by 
























4.1 Paper I: Intestinal estrogen receptor beta suppresses colon inflammation and 
tumorigenesis in both sexes 
Studies in full-body ERβ knockout mice and selective activation of ERβ with ligands have 
previously confirmed the notion that estrogen via ERβ protects aginst CRC (244, 322-325). 
Our group’s research with exogenously expressed ERβ has shown the antiproliferative and 
antitumorigenic effects of ERβ in both colon cancer cell lines (326-329) and xenografts (327). 
Thus, selective activation of ERβ is a potential choice for CRC preventative therapy, but its 
mechanism of action needs to be elucidated. ERβ has been detected in a few immune-related 
organs and some immune cells (225), and it is possible that ERβ could impact CRC 
development through the immune system. The previous studies which explored the role of ERβ 
in CRC using full knockout animals could not exclude possible systemic ERβ effects via the 
immune system. Also, with one exception (324), all studies were conducted only in female 
mice (244, 325). However, ERβ is expressed in colon and rectum in both men and women, 
men also synthesize estrogen (primarily E1), and ERβ can be activated by dietary 
phytoestrogens. Thus, men are also expected to have some ERβ activity. Hence, we here 
attempt to understand the physiological relevancy of ERβ in both sexes using colitis-induced 
CRC (CA-CRC) in male and female mice that lack ERβ, specifically in intestinal epithelium 
(ERβKOVil). We have used the AOM/DSS model to induce CA-CRC, which reflects the 
histopathological and molecular environment of human CA-CRC.  
Using RNAscope and IHC with a validated antibody (225), we confirmed ERβ expression in 
normal colon and rectum epithelia of both human and mouse, and lack of expression in CRC, 
which supports our underlying hypothesis that ERβ can protect against CRC formation. We 
observed that loss of intestinal ERβ increases the number of tumors in males and the tumor size 
in females (Figure 6). One interesting finding is that loss of ERβ increased the pro-
inflammatory cytokine Tnfα expression in both sexes, most prominently in males. Moreover, 
we noted that several TNFα and NFκB target genes, such as Il6 and Il1b, strongly increased 
upon loss of ERβ, following AOM-DSS treatment, especially in males. On the other hand, in 
females, lack of epithelial ERβ increased both ulcerative areas and reduced ulcer healing. We 
have thus demonstrated that both sexes are protected by intestinal ERβ from CRC in a sex-
dependent manner. The tumor size and incidence differences between males and females may 
be partly due to these specificities or microenvironmental signals, and differences in their 
immune system, resulting in different colon epithelial gene expressions between males and 
females.  
We have also previously shown that the microbiota diversity in these mice appeared modulated 
by ERβ (330). To circumvent possible impact by microbiota effects and explore if ERβ could 
protect the epithelial cells from TNFα-induced damage, we treated intestinal organoid cultures 
generated from WT and ERβKOVil mice of both sexes, with TNFα and a selective agonist for 
ERβ (DPN). The ex vivo crypt formation, which quantifies regenerative growth, was decreased 




selective agonist DPN significantly counteracted the TNFα-induced epithelial cell damage but 
did not do so in ERβKOVil mice. This data demonstrates that the activation of intestinal ERβ 
protects both sexes against TNFα-induced epithelial cell damage.   
Further, we explored these molecular mechanisms in two human colon cancer cell lines HT29 
and SW480, using transcriptomic and genome-wide studies. We found that ERβ modulated a 
proportion of the TNFα-regulated transcriptome and inhibited most of these genes in CRC 
cells. Next, we tested whether ERβ can impact the translocation of NFκB subunit p65 or 
transactivation of TNFα. We observed that ERβ affected neither the translocation of p65 nor 
the transactivation of TNFα in either of the cell lines. We could confirm that ERβ modifies the 
expression of NFκB regulated genes also in mice, such as Atf3, Bcl3, and reduces pro-
inflammatory signaling by lowering levels of chemoattractants Ccl2 and Ccl4. NFκB targets 
ATF3, BCL3, and BIRC3 also had ERE elements in close proximity, indicating that ERβ has 
the potential to bind these targets. Using ChIP-qPCR, we have confirmed that ERβ binds to 
NFκB targets, ATF3, BCL3, and BIRC3 in the promoter or enhancer regions, indicating 
biological cross-talk between ERβ and p65. Further, using the ERE-luciferase transactivation 
assay in cell lines, we found that TNFα could enhance the transactivation of ERβ. This suggests 
that an inflammatory condition increases ERβ activity, which successively inhibits TNFα-
mediated signaling and thus reduces the inflammation, implying an inhibitory feedback loop.   
 
Figure 6. (A, B) Intestinal ERβ protects both sexes from colitis-induced CRC in a sex-dependent manner. Loss of 
intestinal ERβ increases the number of tumors in males while increasing the tumor size in females (226). 
In this study, we tested only a limited number of promoter regions. Further performing ERβ 
and p65 ChIP-Seq is significantly more informative and reveals the molecular basis for this 
cross-talk, which is addressed in paper II and IV. In conclusion, our data indicate that ERβ, 
expressed specifically in the intestinal epithelia, protects from colitis-induced CRC in a sex-






4.2 Paper II: Genome-wide estrogen receptor β chromatin binding in human colon cancer 
cells reveals its tumor suppressor activity 
The antitumorigenic effects of ERβ have been previously reported by our group in different 
CRC cell line models, where re-expression of ERβ reduced cell proliferation, migration, and 
invasion (245, 250, 251, 299). In paper I, the deletion of intestinal ERβ in mice enhanced 
tumorigenesis, indicating the importance of colonic ERβ in protecting from tumors. All these 
studies strongly support a role for intestinal ERβ as a target for chemopreventive therapy in 
colon cancers; however, the ERβ mechanisms of action at the chromatin level in colon cells 
have not been studied yet. So far, only a few studies have mapped ERβ binding sites, mostly 
in MCF7 breast cancer cells (16, 17). The ERβ chromatin binding in the colon is unknown. 
To determine colonic tumor protective effects of ERβ through its activity as a transcription 
factor, we aimed to characterize its genome-wide chromatin binding sites and identify its target 
genes in colon. One of the challenges in studying ERβ is its low native expression in tissues 
and its lack of expression in immortalized cancer cell lines (257). Introducing ERβ into cell 
lines is a way of restoring its loss of endogenous expression to study its impacts. For this 
purpose, we performed ChIP-Seq on previously characterized CRC cell lines with transduced 
ERβ expression, HT29-ERβ, and SW480-ERβ (299, 327). The quality of a ChIP-Seq study is 
highly dependent on the specificity and selectivity of the antibody used, and we further 
optimized and evaluated the highly validated ERβ antibody PPZO506 for application in ChIP-
Seq (225).  
We mapped 2977 and 1853 ERβ binding sites in HT29, SW480 cells, respectively. In line with 
previous ER cistrome studies, most ERβ binding sites were located within intronic (43%) and 
intergenic (40%) regions. We found that the majority of binding sites contain canonical ERE 
motif, indicating that ERβ binds directly to DNA with its DNA-binding domain. Further, a 
relatively large proportion exhibited AP-1 motif, indicating its known interaction with the AP-
1 complex. We also discovered motifs (TCF, ELF3, and KLF5) that have not previously been 
associated with ERβ, indicating potential novel cross-talk (Figure 7). Overall, the most 
enriched biological functions among genes closest to ERβ binding sites include cell migration, 
cell-cell adhesion, and transcriptional regulation in both cell lines. These are processes that 
ERβ is known to affect.  
To determine whether ERβ binding is functionally relevant in transcriptional regulation of 
genes, we linked ERβ ChIP-Seq data with corresponding gene expression data from SW480 
and HT29 cells. Associated with ERβ binding sites, ERβ regulated genes are mainly involved 
in proliferative Wnt signaling, NFκB signaling, and insulin-like growth factor signaling 
pathways. We identified that ERβ strongly upregulated CST5, a candidate tumor suppressor in 
colon cancer, and downregulated the LRP6 oncogene, which promotes aberrant β-catenin 
signaling. To transcriptionally regulate the oncogenic Wnt pathway, β-catenin depends on TCF 
family proteins, as it lacks a DNA-binding domain (331). A significant fraction of ERβ-binding 




To investigate whether ERβ impacts the epigenome, we studied the histone acetylation mark 
H3K27ac which represents transcriptionally active enhancers, promoters, in presence and 
absence of ERβ. A significant fraction of H3K27ac binding sites were modulated by the 
presence of ERβ in both HT29 (4159 enhanced, 4835 reduced) and SW480 cells (3793 
enhanced, 3596 reduced). Genes located by ERβ-modulated H3K27ac sites were also 
overrepresented among functions such as cell migration, apoptosis, and Wnt signaling.  
To explore whether or to which extent ERβ binding is tissue-specific, we compared our ERβ 
cistrome data with that of breast cancer cell line MCF7, using the same antibody and method. 
The predominant ERβ-binding motifs in breast were ERE, AP-1, and GATA4. We found no 
enrichment for TCF and KLF motifs in breast, indicating that ERβ tethering with TCF and 
KLF5 is specific to colon cancer and thus cell context dependent. TCF and KLF5 chromatin 
accessibility was dysregulated in polyps associated with CRC invasion, according to a recent 
study that used ATAC-Seq to construct single-cell chromatin maps of polyps and CRC. TCF 
motifs were highly enriched in polyps, indicating increased chromatin accessibility, whereas 
KLF motifs chromatin accessibility was lost during cancer progression (332). KLF4 was also 
identified as a potential tumor suppressor in CRC (333). One could speculate that ERβ directly 
or indirectly competes with β-catenin to bind TCF proteins and controls the genes or regulatory 
elements involved in the early events of polyp transforming into CRC.  
Figure 7. De novo motif analysis identified TCF and AP-1 motifs in ERβ binding sites in both 
colon cancer cell lines (334).    
The use of exogenously expressed ERβ instead of native expression is one of the shortcomings 
of this study, and also that the cell lines are from colon cancer instead of non-tumor colon 
epithelial origin. However, the levels of ERβ in normal epithelial and non-tumor cell lines are 
too low to allow high-quality ChIP-Seq data, and non-tumor colon cell lines are difficult to 
culture and transduce. In conclusion, this study mapped genome-wide ERβ binding sites and 







4.3 Paper III: High-fat diet and estrogen impact the colon and its transcriptome in a sex-
dependent manner 
Sex and lifestyle factors, like dietary factors, are important risk factors in CRC development. 
Intake of a High-fat diet (HFD) affects the colon first and modulates intestinal permeability, 
microbiota composition, and induces inflammation (81-83). A meta-analysis of 56 cohort and 
case-control studies found that obesity increases the risk of CRC, and a 5 kg/m2 increase in 
body mass index (BMI) increases the risk of CRC development by 18%, and a BMI above 
30 kg/m2 increases the risk by 41% (79). Obesity impacts inflammation, gut microbiota, 
hormones such as estrogen, insulin, and leptin which all play a role in CRC (335, 336). Estrogen 
has shown to protect against obesity and metabolic syndromes, as reviewed in (337). In study 
I, we also found that ERβ protects from CRC in a sexually dimorphic manner, with more 
tumors in males and larger tumors in females. However, no studies have been conducted to 
investigate colonic sex differences in relation to obesity, metabolic dysregulation, and 
estrogenic ligands. In this study, we focused on determining if estrogen affects the colon 
microenvironment during HFD-induced inflammation and on dissecting sex differences. For 
13 weeks, we fed mice an HFD with 60% fat or a control diet (CD) with 10% fat. In the last 
three weeks prior sacrifice, mice were treated with different estrogenic ligands. To investigate 
sex differences on the colon transcriptome, we performed RNA-Seq on male and female distal 
colon tissues. 
The colon transcriptome of CD-fed mice revealed that a high proportion of genes (1564) were 
differentially expressed between males and females. Under HFD treatment, the sex difference 
was less prominent, with 364 differentially expressed genes. About a quarter of the 
transcriptomic sex differences found under HFD were also observed under CD. Among these 
stable sex difference genes, the most overrepresented genes belonged to the circadian rhythmic 
pathway and included key genes Npas2 and Bmal1(Arntl), which were higher expressed in 
females compared to males. Further, separate comparisons showed that HFD modulated 
different genes in the sexes. Significantly overrepresented functions of genes regulated in males 
were cell cycle and hypoxia, while for females, it was lipid metabolism, steroid hormone, and 
Wnt signaling. Hypoxia can induce inflammation, and in IBD, hypoxia-inducible factors (HIF-
1α and HIF-2α) are highly present (338). In paper I, we also found strong inflammatory 
signaling and significantly increased Il6 and Il1b in WT males compared to WT females, 
suggesting sex differences. We also identified that HFD-induced sex differences in colon 
length (a shortened colon is indicative of inflammation), fasting glucose, and crypt 
proliferation. A shorter colon was found only in males but not in females. Further, HFD 
increased crypt proliferation and fasting glucose levels in males but not in females. On the 







To determine if ERβ could modulate inflammation, we treated mice with estradiol (E2, 
activates all ERs), a ligand selective for ERα (PPT), and a ligand selective for ERβ (DPN). 
Treatment with E2 opposed the HFD-induced gene expression, particularly on genes involved 
in metabolic processes and inflammation. These results clearly indicate that E2 opposes the 
HFD dysregulated transcriptome, possibly through ERs present in the colon or through 
improved metabolism in general (Figure 8A). E2 and PPT both controlled body weight gain 
and total fat, which impacts the overall metabolic profile, which is in accordance with previous 
studies indicating that E2 through ERα reduces food intake (339) and regulates the body fat 
distribution (340). The impact in the colon was mainly seen through E2 and DPN, which 
counteracted HFD-induced F4/80+ colon macrophage infiltration in both sexes and Ki67 
proliferation in colon crypts of males. All three ligands E2, DPN, and PPT significantly 
restored the HFD reduced Bmal1 gene in females. We further identified ERβ binding to 
BMAL1 and NPAS2 using ChIP-Seq data (from paper II) and correspondingly decreased gene 
expression of Bmal1 and Npas2 in the female colon with loss of intestinal ERβ (Figure 8B-D). 
This study concludes that HFD impacts the colon microenvironment with prominent sex 
differences. Estrogen modulates the HFD induced transcriptome and, through ERβ, counteracts 
HFD-dysregulated clock genes, macrophage infiltration, and cell proliferation in a sex-
dependent manner.  
 
Figure 8. (A, B) E2 opposes the majority of HFD induced gene dysregulation in colon microenvironment, such 
as dysregulation of clock genes BMAL1 and NPAS2 in males (C). Interestingly, we identified ERβ binds to clock 
genes in colon cancer cells using ChIP-Seq (D) The clock genes were dysregulated specifically in the absence of 






4.4 Paper IV: Estrogen receptor beta influences the inflammatory p65 cistrome in colon 
cancer cells. 
In paper I, we showed that ERβ protects against epithelial damage by repressing TNFα 
signaling in vivo. ERβ also binds in the vicinity of NFκB target genes and modulates the 
expression of TNFα regulated transcriptome in CRC cell lines. In paper II, we also find that 
ERβ chromatin-binding sites were enriched adjacent to genes involved in NFκB signaling. The 
ERs can interact with other transcription factors to promote or suppress transcription. In 
particular, a cross-talk between ERα and NFκB in breast cancer has been identified, and some 
studies (191, 192) support that ERα inhibits NFκB activity; on the contrary, other studies claim 
that ERα promotes NFκB activity (193, 194). The DNA binding domain is highly conserved 
between ERα and ERβ, but the two proteins differ significantly in their N-terminal domains 
and their ligand-binding domains (134, 136). Therefore, we hypothesized that ERβ 
transcriptionally modulates NFκB signaling by modulating its chromatin binding at the 
genome-wide level, for example, through protein-protein interaction or chromatin-binding 
competition. To experimentally demonstrate interactive cross-talk between p65 and ERβ, we 
performed p65 ChIP-Seq in CRC cells upon TNFα treatment in presence and absence of ERβ 
and compared with corresponding gene expression data.  
We identified 3151 and 1459 p65 binding sites in HT29 and SW480 cells. They were located 
by genes involved in known biological functions such as TNFα signaling, cell migration, 
apoptosis, and more particularly circadian rhythm. The circadian rhythm has not been linked 
to p65 before, and this novel potential role in the colon paves the way for new studies. To 
compare p65 cistrome between different tissues, we have used publicly available p65 ChIP-
Seq data from MCF7 cells (also performed using double crosslinking). Comparison of p65 
chromatin-binding sites revealed that to a large extent, they are different between the breast 
and colon cancer cell lines, indicating that NFκB works uniquely to control transcriptional 
regulation in different cancers. The two p65 ChIP-Seq studies used different antibodies and 
protocols, which might also impact this comparison.  
Further, we identified that ERβ modulates p65 chromatin binding in both CRC cells but in a 
cell line-specific manner. In paper III, we showed that ERβ restores the core clock genes 
dysregulated by HFD. Here, in paper IV, we found that ERβ modulates the p65 binding to core 
circadian genes CLOCK and BMAL2, further strengthening the intrinsic cross-talk between 
ERβ, clock genes, and p65. In HT29 cells, ERβ generally reduced p65 chromatin binding while 
it increased p65 binding in SW480 cells. However, in terms of gene expression, ERβ reduced 
p65 transcriptional activity in both cell lines. It is possible that biological, genetic, or epigenetic 
changes between HT29 and SW480 cell lines impact this cross-talk. Some notable differences 
are that the SW480 cell line contains double mutant p53 alleles (298), whereas HT29 has a 
single p53 mutation, which might result in different chromatin complexes with p65. Previous 
studies showed p53 and p65 interactions in various cancers with different outcomes (342-344), 




binding (345). Also, HT29 is a female cell line, while SW480 has a male background. Our 
results should be verified with more cell lines to further understand this cross-talk.  
Some methodological and potential shortcomings of this study include that cells were treated 
with different TNFα timings and concentrations for the Chip-Seq study compared with the gene 
expression experiments. Genomic binding occurs immediately after p65 translocation, and we 
have therefore used 30 minutes TNFα treatment for ChIP-Seq experiments. The regulation of 
gene expression by p65 is a slightly later event as it occurs after chromatin binding and the 
mRNA remains in the cell for a longer time; hence we used a 2-hour treatment for gene 
expression analysis. In paper II, we demonstrated that ERβ chromatin binding occurs 
independently of ligand in the CRC cell lines. ERβ has previously been shown to have ligand-
independent functions in cell lines, which may be a consequence of overexpression or that the 
high level of growth factors activates ERβ through phosphorylation. Hence, we did not treat 
the cells with E2 to activate ERβ. Furthermore, the addition of TNFα to estrogen (E2) treatment 
in the MCF-7 breast cancer cells has been reported to alter the ERα enhancer landscape in an 
NFκB-dependent manner (275). In future studies, it would be interesting to investigate whether 
the ERβ cistrome is affected by TNFα treatment. Here, we defined how ERβ modulated p65 
chromatin binding in colon cancer cells and provided the mechanistic basis for understanding 
the p65 cistrome and corresponding TNFα-induced response; further revealing a cross-talk 
between ERβ and the NFκB pathway (Figure 9). 
                           
Figure 9. Schematic summary model of ERβ genomic binding and cross-talk with potential transcriptional 
factors such as p65, AP-1 and TCF motifs and the regulated genes are involved in inflammatory and cellular 




In conclusion, our data indicate that intestinal ERβ is protective against CA-CRC in a sex-
dependent manner by attenuating the TNFα-NFκB pathway. Through genome-wide binding 
studies and transcriptomic studies, we demonstrate that ERβ regulates several tumor 
suppressors and oncogenes involved in CRC progression. We identified that ERβ impacts the 
p65 cistrome and, in particular, regulates circadian clock genes and modulates p65 chromatin 
binding to circadian clock genes. Estrogen through ERβ also protects against HFD-induced 











The following are the major findings of this research: 
• Loss of intestinal ERβ enhances CRC in a sex-dependent manner, increasing the 
incidence of tumors in males and tumor size in females. This suggests that ERβ, which 
is present in the intestinal epithelial cells, is protective against CRC.  
• ERβ attenuates TNFα-induced epithelial cell damage and reduces inflammation, as 
well as impacts intestinal crypt cell proliferation.   
• In colon cancer cells, ERβ binds and regulates several important tumor suppressors and 
oncogenes involved in the oncogenic Wnt/β-catenin pathway and NFκB signaling. 
Novel major motifs identified in ERβ chromatin binding sites include TCF and KLF 
motifs. This indicates potential genomic cross-talk between ERβ and TCF and KLF 
factors. 
• Estrogen via ERβ protects against the HFD-induced pro-inflammatory condition. 
Selective activation of ERβ with DPN reduced macrophage infiltration and epithelial 
cell proliferation. Intestinal ERβ restored the HFD dysregulated clock genes expression 
in vivo.  
• ERβ attenuates the TNFα transcriptome in CRC cell lines and modifies p65 chromatin 
binding in a cell line-dependent manner. It also modulates the expression of NFκB 
target genes. ERβ impacts p65 chromatin binding to core clock genes in CRC cell lines.  
• The circadian clock is essential to maintain gut function, inflammation, and 
metabolism, and ERβ regulating this may be imperative for its protective activity.  This 
indicates a key role for ERβ in the regulation of clock genes, providing a novel approach 












6 FUTURE PERSPECTIVES 
The studies conducted with our animal model ERβKOVil suggest that loss of intestinal ERβ 
aggravates CRC and enhances TNFα signaling. We recently also performed RNA-sequencing 
of WT and ERβKOVil colon to investigate the protective effects of ERβ. In the future, it would 
be interesting to perform both AOM-DSS and HFD studies in a recently developed novel 
transgenic mouse model Gt(ROSA)26Sor with ERβ overexpression (iERβ+). Endogenous 
ERβ expression is very low in the colon, and it would be fascinating to compare the results 
with the ERβ knock-in model. This would help advance our understanding of the localized 
impact of intestinal ERβ on colon microenvironment during colitis and HFD-induced obesity. 
Future studies should also focus on the effects of restoring ERβ expression in adenomas (pre-
stage of CRC) using an inducible intestinal ERβ mouse model. This would add to our 
understanding of whether restoring ERβ in tumors could exert anti-tumorigenic effects. 
Further, investigating approaches to restore ERβ expression in the advanced stages of CRC, as 
has been reported in polyps by certain phytoestrogenic/lignan complexes. Several doxycycline-
inducible mouse models available are not suitable for colon studies, as doxycycline impacts 
the gut microbiome by decreasing bacterial diversity, richness (346), and metabolism (347). 
Developing safe inducible intestinal ERβ mouse models could enable us to further explore ERβ 
activity in detail.  
My cistrome data identified novel evidence of interaction between ERβ and TCF and KLF 
motifs. More insight into this cross-talk can be achieved from CO-IP or possibly IP-MS. Recent 
methodological developments such as RIME (rapid immunoprecipitation mass spectrometry 
of endogenous proteins) or quantitative multiplexed RIME methods further help to explore 
protein interactions in complex chromatin heterogeneity (348, 349). Simultaneously, exploring 
ERβ interaction with AP1 or nuclear receptors expressed in colon is also essential to target NR 
cross-talk. In the future, this would help to design ligands to improve or restrict transcription 
factor cross-talk. So far, due to low levels of ERβ expression in the colon, it is challenging to 
perform ChIP-Seq using endogenous expression of ERβ. The iERβ+ mouse would also provide 
an opportunity to further corroborate the ChIP-Seq results in vivo.  
In this study, we sequenced E2-activated ERβ ChIP samples. However, we also demonstrated 
(at a few selected sites) that the DNA binding of ERβ is ligand-independent in these cell lines. 
The reason for this is not known. In COS1 cells, it has been shown that EGF (epidermal growth 
factor) induces phosphorylation of serine residues (S104, S124) of ERβ and activates its 
interaction with steroidal co-receptor activator 1 (SRC-1), and this results in ligand-
independent activity (350, 351).  However, we cannot rule out the possibility that the E2 
independence results from ERβ overexpression. In this regard, it is also interesting to perform 
ChIP-Seq without E2 ligand and compare both cistromes to determine if there is any difference 
present, in some or a proportion of binding sites, between ligand-activated ERβ and ligand-





In the HFD study, we have studied how ERβ impacts HFD-induced dysregulation of clock 
genes at only one time point. Further analyzing this at different Zeitgeber time points 
throughout the day will help to identify how ERβ affects circadian rhythmicity. We observed 
substantial sex differences in the colon transcriptome of mice. Another study from our group 
recently identified sexual dimorphism in humans in normal colon and colon cancer 
transcriptomes and presented sex-specific prognostic CRC biomarkers (352). Such sex 
differences may help to explain the difference in CRC incidence, tumor characteristics, and 
mortality between men and women. Altogether, it appears imperative that future studies of 
CRC and colon consider sex in their design.  
My Ph.D. studies have made an interesting finding that p65 binding to circadian clock genes 
in colon cancer cells. More insights into this regulation could help to understand this novel 
finding. I have revealed that the ERβ impact on p65 activity is cell-type dependent. Also, our 
data shows an interesting feedback loop mechanism in which TNFα transactivates ERβ, which 
in turn inhibits TNFα signaling. Therefore, further research into TNFα-P65-ERβ cross-talk, in 
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